Engage with Pluri's Talent: Exciting Conference Appearances Ahead
19 March 2024 - 7:00PM
Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a
leading biotechnology company that transforms cells into solutions
that promote global wellbeing and sustainability, today announced
its participation in the following upcoming conferences.
Conference: Bio-Europe
SpringDate: March 18-20, 2024Location: BarcelonaPluri’s
Chief Business Development Officer-Pharma Efrat
Kaduri will attend the event. BIO-Europe Spring connects
the global biopharma community to elevate life science
partnerships, bringing together over 3,700 attendees from 2,000+
companies to engage in 20,000 one-on-one meetings.
Conference: Advanced Therapies
2024Date: March 19-20, 2024Location: LondonPluri’s
Chief Technology Officer Lior Raviv will
participate in a panel discussion titled: Points to consider when
building supply chain operations from scratch on Tuesday, March 19,
2024 at 1:40 PM. He will also give a presentation titled:
Unleashing the Allogeneic Potential by Using Large Scale Automated
Manufacturing Platforms on Wednesday, March 20, 2024 at 2:40
PM.Pluri’s Chief Commercial Officer PluriCDMO Andy
Lewin will attend the event. The Advanced Therapies
congress is Europe’s largest cell and gene therapy conference and
exhibition. The event brings together the world leaders in advanced
therapy medicinal product development and the most senior
executives in charge of the latest tech and strategies that are
driving the industry forward.
Conference: CISH Impact Investments
Holdings ConferenceDate: March 28, 2024Location: Online
EventPluri’s Chief Executive Officer & President Yaky
Yanay will be presenting at the conference on Thursday,
March 28, 2024 at 2:20 PM.CISH Impact Investments Holdings
Conference is a global event on impact opportunities and
investments in promising technology companies that have a positive
impact on the community and the environment.
Meetings with the Pluri team can be scheduled
via the various conference partnering engines or via email at
info@pluri-biotech.com
About Pluri
Pluri is pushing the boundaries of science and engineering to
create cell-based products for commercial use and is pioneering a
biotech revolution that promotes global wellbeing and
sustainability. The Company’s technology platform, a patented and
validated state-of-the-art 3D cell expansion system, advances novel
cell-based solutions for a range of initiatives— from medicine and
climate change to food scarcity, animal cruelty and beyond. Pluri’s
method is uniquely accurate, scalable, cost-effective, and
consistent from batch to batch. Pluri currently operates in the
field of regenerative medicine, food-tech and agtech and aims to
establish partnerships that leverage the Company’s 3D cell-based
technology to additional industries that require effective, mass
cell production. Pluri also offers CDMO services. To learn more,
visit us at http://www.pluri-biotech.com or follow us on LinkedIn
and X.
Media Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at Shacharye@gitam.co.il
U.S. Media: Madeline Weirman at Maddie@quantum-corp.com/ Jessica
Daitch at Jessica@quantum-corp.com
Pluri (NASDAQ:PLUR)
Historical Stock Chart
From Dec 2024 to Jan 2025
Pluri (NASDAQ:PLUR)
Historical Stock Chart
From Jan 2024 to Jan 2025